Why would specialists use biosimilars? Can you discuss how rheumatologists and pharmacists make cost reduction-based clinical decisions when selecting anti-TNF biologics in the setting of RA, AS, psoriatic arthritis and related conditions?

Why would specialists use biosimilars? Can you discuss how rheumatologists and pharmacists make cost reduction-based clinical decisions when selecting anti-TNF biologics in the setting of RA, AS, psoriatic arthritis and related conditions?

Why would specialists want to use biosimilars in their practice? Can you discuss how rheumatologists and pharmacists should make important cost reduction-based clinical decisions when selecting anti-TNF biologics, based on primary differences between biosimilar therapies and their reference biologic agents in the setting of RA, AS, psoriatic arthritis and related conditions?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Leonard Calabrese, DO

Leonard Calabrese, DO

Professor of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Vice Chairman Department of Rheumatic and Immunologic Diseases
Orthopaedic and Rheumatologic Institute